前沿生物技术路演专场（上午）

返回主日程
09:00 - 12:15
  • 主持人 Moderator
  • 姬勋, 齐济投资投资总监
  • Jason JI, Investment Director of TTM Capital
    • 交流嘉宾 Invited Discussants:
  • 梁艳, 南京医科大学第一附属医院副主任医师
  • LIANG Yan, Associate Chief Physician,The First Affiliated Hospital with Nanjing Medical University
  • 袁建伟, 祥峰投资合伙人
  • YUAN Jianwei, Partner, Vertex Ventures
  • 贺菊颖, 中信建投证券研究发展部联席负责人、未来产业和政策研究院执行院长
  • HE Juying, Co-Head of Research & Development Department, China Securities Co., Ltd.; Executive Dean of the Institute for Future Industries and Policy
  • 姬勋, 齐济投资投资总监
  • Jason JI, Investment Director of TTM Capital
09:00 - 09:20
  • 主题报告
  • Keynote Speech
  • 新兴生物技术赛道的价值重估与投资机遇
  • Value Re-rating and Investment Opportunities in Emerging Biotechnology
  • 贺菊颖, 中信建投证券研究发展部联席负责人、未来产业和政策研究院执行院长
  • HE Juying, Co-Head of Research & Development Department, China Securities Co., Ltd.; Executive Dean of the Institute for Future Industries and Policy
09:20 - 09:45
  • 项目 1
  • Project 1
  • 基于VHH纳米抗体的吸入式/口服式大分子创新药平台
  • Innovative Inhaled and Oral Large-Molecule Therapeutics Platform Based on VHH Nanobodies
  • 李光辉, 上海洛启生物医药技术有限公司商务总监
  • LI Guanghui, Business Director,Shanghai Novamab Biopharmaceuticals Co., Ltd.
09:45 - 10:10
  • 项目 2
  • Project 2
  • 辐联科技——构建领先的全面整合型放射性药物平台
  • Full-Life: Building a leading, fully intergrated radiopharmaceutical platform
  • 胡泰山, 上海辐联医药科技有限公司高级副总裁，药物化学负责人
  • HU Taishan, Senior Vice President, Head of Medicinal Chemistry of Full-Life Technologies
10:10 - 10:35
  • 项目 3
  • Project 3
  • 精准治疗小分子偶联SMDC新药及技术平台
  • Precision SMDC Therapeutics and Technology Platform
  • 贺玖明, 中国医学科学院药物研究所研究员
  • HE Jiuming, Professor,Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College
10:35 - 11:00
  • 项目 4
  • Project 4
  • PD-L1×VEGF双特异性抗体偶联药物(B016)用于一线治疗驱动基因阴性晚期非鳞非小细胞肺癌
  • A PD-L1×VEGF Bispecific Antibody Drug Conjugate (B016) for the First-line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer with Negative Driver Genes
  • 唐清林, 甫康生物科技（上海）股份有限公司首席技术官
  • TANG Qinglin, Chief Technology Officer,Convalife Pharmaceuticals, Ltd.
11:00 - 11:25
  • 项目 5
  • Project 5
  • 长效靶向TSLP纳米抗体吸入粉雾剂（CXX169）的研究与开发
  • Development of Inhaled Long‑acting anti-TSLP Nanobody(CXX169)
  • 赵国宝, 杭州畅溪制药有限公司高级副总裁
  • ZHAO Guobao, Senior Vice President,Hanzhou Chance Pharmaceuticals Co.,Ltd
11:25 - 11:50
  • 项目 6
  • Project 6
  • 用于治疗脊索瘤的新型XDC偶联药物开发
  • Development of Novel XDC Conjugate Drugs for the Treatment of Chordoma
  • 李燕, 中国医学科学院药物研究所副研究员
  • LI Yan, Chief Executive Officer,Associate Research Scientist,Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
11:50 - 12:15
  • 项目 7
  • Project 7
  • 双荷载ADC技术平台
  • CRC Dual-payload ADC Programs
  • 尹茂, 普灵生物医药（深圳）有限公司首席执行官
  • YIN Mao, Founder & CEO , PrimeLink BioTherapeutics